You are here

  • Home
  • Archive
  • Volume 16, Issue 4
  • Catheter-based renal sympathetic denervation reduces systolic blood pressure by 32 mm Hg in people with treatment-resistant hypertension

Article Text

Article menu
Download PDFPDF
Therapeutics
Randomised controlled trial
Catheter-based renal sympathetic denervation reduces systolic blood pressure by 32 mm Hg in people with treatment-resistant hypertension
  1. Richard E Katholi1,
  2. Krishna J Rocha-Singh1
  1. 1Prairie Cardiovascular Consultants, Springfield, Illinois, USA
  1. Correspondence to Richard E Katholi
    Prairie Cardiovascular Consultants, PO Box 19420, Springfield, IL 62794-9420, USA; rkatholi{at}prairieheart.com

https://doi.org/10.1136/ebm1194

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Esler MD, Krum H, Sobotka PA, et al.; Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010;376:1903–9.OpenUrlCrossRefPubMedWeb of Science

    Context

    The kidney plays an essential role in the regulation of blood pressure through sodium, volume, renin modulation and renal-sympathetic neuronal interactions. Over many years, the contribution of the renal nerves has been investigated by renal denervation in experimental animal models and by mainly indirect techniques in humans.1 2 Depending on the setting, the contribution to hypertension may be mediated mainly by activation of the efferent or afferent sympathetic renal nerves which lie within and immediately adjacent to the wall of the renal arteries. As the causative factors of …

    View Full Text

    Footnotes

    • Competing interests None.